欢迎来到《四川大学学报(医学版)》
周惠君, 董萍, 蔡华伟等. 含神经纤毛蛋白-1靶向序列的细胞穿透肽的合成及其与非小细胞肺癌的特异性结合研究[J]. 四川大学学报(医学版), 2016, 47(1): 19-22.
引用本文: 周惠君, 董萍, 蔡华伟等. 含神经纤毛蛋白-1靶向序列的细胞穿透肽的合成及其与非小细胞肺癌的特异性结合研究[J]. 四川大学学报(医学版), 2016, 47(1): 19-22.
ZHOU Hui-jun, DONG Ping, CAI Hua-wei. et al. Cellular Uptake and Localization of Novel NSCLC Penetrating Peptide with Neuropilin-1 Binding Motif[J]. Journal of Sichuan University (Medical Sciences), 2016, 47(1): 19-22.
Citation: ZHOU Hui-jun, DONG Ping, CAI Hua-wei. et al. Cellular Uptake and Localization of Novel NSCLC Penetrating Peptide with Neuropilin-1 Binding Motif[J]. Journal of Sichuan University (Medical Sciences), 2016, 47(1): 19-22.

含神经纤毛蛋白-1靶向序列的细胞穿透肽的合成及其与非小细胞肺癌的特异性结合研究

Cellular Uptake and Localization of Novel NSCLC Penetrating Peptide with Neuropilin-1 Binding Motif

  • 摘要: 目的 设计一类具有C末端基序的新型肿瘤穿透肽YCCS,并检测其对非小细胞肺癌的靶向结合能力。方法 设计了融合肺癌靶向肽段CS及神经纤毛蛋白-1靶向肽段CRMP-1的新型多肽YCCS,采用Fmoc固相合成法合成多肽,并在多肽上标记荧光素FITC,以神经纤毛蛋白-1阳性的非小细胞肺癌A549、人乳腺癌MDA-MB-231,以及神经纤毛蛋白-1阴性的正常人肺成纤维细胞HBE135-E6E7、正常人肝细胞HL-7702为研究对象,观察荧光标记的多肽与A549细胞的特异性结合能力。结果 成功设计并合成了肿瘤穿透肽FITC-YCCS用于细胞结合研究,荧光细胞结合实验证实,在5 μmol/L浓度下,YCCS多肽能特异性的与非小细胞肺癌A549结合,而基本不与乳腺癌细胞及正常细胞结合。随多肽浓度升高,在20 μmol/L浓度下,YCCS多肽与乳腺癌细胞MDA-MB-231和肝细胞HL-7702出现少量结合。结论 本研究设计的肿瘤穿透肽YCCS在5 μmol/L浓度下,可检测到对非小细胞肺癌A549具有特异性结合能力。

     

    Abstract: Objective To synthesize and study the specific binding affinity of tumor-penetrating peptide YCCS to non-small cell lung carcinoma (NSCLC) cells in vitro. Methods YCCS peptide was designed by fusing the neuropilin-1 (NRP-1) binding sequence and NSCLC binding peptide CS. YCCS peptide was synthesized and fluorescent labeled with N-terminal FITC.NRP-1 positive human NSCLC cell A549, NRP-1 positive human breast cancer cell MDA-MB-231, normal human bronchial epithelium HBE135-E6E7 and human liver cell HL-7702 were incubated respectively,then we observed the specific binding affinity of tumor-penetrating peptide YCCS to NSCLC cells. Results After treated with 5 μmol/L peptide, significant fluorescent signals of FITC-YCCS peptide were demonstrated only in NSCLC A549 cells but marginal captured signal in MDA-MB-231, normal human HBE135-E6E7 or HL-7702 cells, which revealed specific NSCLC cells binding affinity. In 20 μmol/L treated group, non-specific binding were found in MDA-MB-231 and HL-7702 cells. Conclusion The results of this novel designed YCCS peptide indicated a promising strategy for improving tumor penetrating with delivery capability of drugs to NSCLC A549 cells when treated with 5 μmol/L peptide.

     

/

返回文章
返回